ArticleTherapeutic advances in medical oncology2020

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.

Reem Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.